Parathyroid hormone, a crucial mediator of pathologic cardiac remodeling in Aldosteronism

Cardiovascular Drugs and Therapy

Volumn 27, Issue 2, 2013, Pages 161-170

  Rutledge, Michael R ^a   Farah, Victor ^a   Adeboye, Adedayo A ^a   Seawell, Michael R ^a   Bhattacharya, Syamal K ^a   Weber, Karl T ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Aldosteronism; Cardiac fibrosis; Cardiomyocyte necrosis; Intracellular Ca2+ overloading; Mitochondria permeability transition pore; Oxidative stress; Parathyroid hormone

Indexed keywords

ADENOSINE TRIPHOSPHATE; CALCIUM ION; MAGNESIUM ION; PARATHYROID HORMONE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE;

ALDOSTERONE RELEASE; ARTICLE; CALCIUM CELL LEVEL; CARDIAC REMODELING; CELL DEATH; DISEASE ASSOCIATION; HEART DISEASE; HEART HEMODYNAMICS; HEART MUSCLE CELL; HORMONE ACTION; HUMAN; HYPERALDOSTERONISM; HYPOCALCEMIA; HYPOMAGNESEMIA; INTRACELLULAR SIGNALING; MEMBRANE PERMEABILITY; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; OXIDATIVE STRESS; PARATHYROID HORMONE RELEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; SECONDARY HYPERPARATHYROIDISM;

ALDOSTERONE; ANIMALS; HUMANS; HYPERALDOSTERONISM; PARATHYROID HORMONE; VENTRICULAR REMODELING;

EID: 84876744034     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-012-6378-0     Document Type: Article

References (139)

1. Dluhy RG, Williams GH. Aldosterone-villain or bystander? N Engl J Med. 2004;351:8-10.
2. Funder JW, Reincke M. Aldosterone: A cardiovascular risk factor? Biochim Biophys Acta. 2010;1802:1188-92.
3. FritschNeves M, Schiffrin EL. Aldosterone: A risk factor for vascular disease. Curr Hypertens Rep. 2003;5:59-65.
4. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-17.
5. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-21.
6. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11-21.
7. Weber KT. From inflammation to fibrosis: A stiff stretch of highway. Hypertension. 2004;43:716-9.
8. Resnick LM, Müller FB, Laragh JH. Calcium-regulating hormones in essential hypertension. Relation to plasma renin activity and sodium metabolism. Ann Intern Med. 1986;105:649-54.
9. Resnick LM, Nicholson JP, Laragh JH. Calcium, the reninaldosterone system, and the hypotensive response to nifedipine. Hypertension. 1987;10:254-8.
10. Shane E,Mancini D, Aaronson K, Silverberg SJ, SeibelMJ, Addesso V, et al. Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am J Med. 1997;103:197-207.
11. Alsafwah S, LaGuardia SP, Nelson MD, Battin DL, Newman KP, Carbone LD, et al. Hypovitaminosis D in African Americans residing in Memphis, Tennessee with and without heart failure. Am J Med Sci. 2008;335:292-7.
12. LaGuardia SP, Dockery BK, Bhattacharya SK, Nelson MD, Carbone LD, Weber KT. Secondary hyperparathyroidism and hypovitaminosis D in African-Americans with decompensated heart failure. Am J Med Sci. 2006;332:112-8.
13. Rossi E, Sani C, Perazzoli F, Casoli MC, Negro A, Dotti C. Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas. Am J Hypertens. 1995;8:884-93.
14. Resnick LM, Laragh JH. Calcium metabolism and parathyroid function in primary aldosteronism. Am J Med. 1985;78:385-90.
15. Massry SG, Smogorzewski M. Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia. Semin Nephrol. 1994;14:219-31.
16. Epstein M. Aldosterone blockade: An emerging strategy for abrogating progressive renal disease. Am J Med. 2006;119:912-9.
17. Rosenberg J, Pines M, Hurwitz S. Response of adrenal cells to parathyroid hormone stimulation. J Endocrinol. 1987;112:431-7.
18. Rosenberg J, Pines M, Hurwitz S. Stimulation of chick adrenal steroidogenesis by avian parathyroid hormone. J Endocrinol. 1988;116:91-5.
19. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, Langenbach J, Willenberg HS, Barthel A, et al. Human adipocytes secrete mineralocorticoid- releasing factors. Proc Natl Acad Sci U S A. 2003;100:14211-6.
20. Wang H, Shimosawa T, Matsui H, Kaneko T, Ogura S, Uetake Y, et al. Paradoxical mineralocorticoid receptor activation and left ventricular diastolic dysfunction under high oxidative stress conditions. J Hypertens. 2008;26:1453-62.
21. Goodfriend TL, Ball DL, Egan BM, Campbell WB, Nithipatikom K. Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension. 2004;43:358-63.
22. Payet MD, Goodfriend TL, Bilodeau L, Mackendale C, Chouinard L, Gallo-Payet N. An oxidized metabolite of linoleic acid increases intracellular calcium in rat adrenal glomerulosa cells. Am J Physiol Endocrinol Metab. 2006;291:E1160-7.
23. Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol. 1993;25:563-75.
24. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosterone-induced inflammation in the rat heart. Role of oxidative stress. Am J Pathol. 2002;161:1773-81.
25. Chhokar VS, Sun Y, Bhattacharya SK, Ahokas RA, Myers LK, Xing Z, et al. Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation. 2005;111:871-8.
26. Takeda Y. Effects of eplerenone, a selective mineralocorticoid receptor antagonist, on clinical and experimental salt-sensitive hypertension. Hypertens Res. 2009;32:321-4.
27. Manning Jr RD, Tian N, Meng S. Oxidative stress and antioxidant treatment in hypertension and the associated renal damage. Am J Nephrol. 2005;25:311-7.
28. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricle in experimental hypertension. Circ Res. 1990;67:1355-64.
29. Laurent GJ. Dynamic state of collagen: pathways of collagen degradation in vivo and their possible role in regulation of collagen mass. Am J Physiol. 1987;252:C1-9.
30. López B, González A, Díez J. Circulating biomarkers of collagen metabolism in cardiac diseases. Circulation. 2010;121:1645-54.
31. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. Circulation. 2002;105:1387-93.
32. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. Circulation. 2002;105:1503-8.
33. Díez J. Towards a new paradigm about hypertensive heart disease. Med Clin North Am. 2009;93:637-45.
34. Pearlman ES, Weber KT, Janicki JS, Pietra G, Fishman AP. Muscle fiber orientation and connective tissue content in the hypertrophied human heart. Lab Invest. 1982;46:158-64.
35. Huysman JAN, Vliegen HW, Van der Laarse A, Eulderink F. Changes in nonmyocyte tissue composition associated with pressure overload of hypertrophic human hearts. Pathol Res Pract. 1989;184:577-81.
36. Sun Y, Ramires FJA, Weber KT. Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. Cardiovasc Res. 1997;35:138-47.
37. Weber KT. Aldosterone in congestive heart failure. N Engl J Med. 2001;345:1689-97.
38. Young M, Fullerton M, Dilley R, Funder J. Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest. 1994;93:2578- 83.
39. Garnier A, Bendall JK, Fuchs S, Escoubet B, Rochais F, Hoerter J, et al. Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-Transgenic mice. Circulation. 2004;110:1819-25.
40. Sheppard K, Funder JW.Mineralocorticoid specificity of renal type I receptors: in vivo binding studies. Am J Physiol. 1987;252:E224- 9.
41. Suki WN, Schwettmann RS, Rector Jr FC, Seldin DW. Effect of chronic mineralocorticoid administration on calcium excretion in the rat. Am J Physiol. 1968;215:71-4.
42. Massry SG, Coburn JW, Chapman LW, Kleeman CR. The effect of long-Term desoxycorticosterone acetate administration on the renal excretion of calcium and magnesium. J Lab ClinMed. 1968;71:212- 9.
43. Gehr MK, Goldberg M. Hypercalciuria of mineralocorticoid escape: clearance and micropuncture studies in the rat. Am J Physiol. 1986;251:F879-88.
44. Cappuccio FP, Markandu ND, MacGregor GA. Renal handling of calcium and phosphate during mineralocorticoid administration in normal subjects. Nephron. 1988;48:280-3.
45. Rastegar A, Agus Z, Connor TB, Goldberg M. Renal handling of calcium and phosphate during mineralocorticoid "escape" in man. Kidney Int. 1972;2:279-86.
46. Zikos D, Langman C, Gafter U, Delahaye B, Lau K. Chronic DOCA treatment increases Ca absorption: role of hypercalciuria and vitamin D. Am J Physiol. 1986;251:E279-84.
47. Rossi E, Perazzoli F, Negro A, Sani C, Davoli S, Dotti C, et al. Acute effects of intravenous sodium chloride load on calcium metabolism and on parathyroid function in patients with primary aldosteronism compared with subjects with essential hypertension. Am J Hypertens. 1998;11:8-13.
48. Berthelot A, Pernot F, Gairard A. Influence of the thyroid and parathyroid glands on magnesium metabolism during mineralocorticoid treatment (DOCA+NaCl) in the rat. Ann Nutr Metab. 1983;27:349-54.
49. Horton R, Biglieri EG. Effect of aldosterone on the metabolism of magnesium. J Clin Endocrinol Metab. 1962;22:1187-92.
50. Zou AP, Cowley Jr AW. Role of nitric oxide in the control of renal function and salt sensitivity. Curr Hypertens Rep. 1999;1:178-86.
51. Granger JP, Kassab S, Novak J, Reckelhoff JF, Tucker B, Miller MT. Role of nitric oxide in modulating renal function and arterial pressure during chronic aldosterone excess. Am J Physiol. 1999;276:R197-202.
52. Rondón LJ, Groenestege WM, Rayssiguier Y, Mazur A. Relationship between low magnesium status and TRPM6 expression in the kidney and large intestine. Am J Physiol Regul Integr Comp Physiol. 2008;294:R2001-7.
53. Morrissey JJ, Cohn DV. The effects of calcium and magnesium on the secretion of parathormone and parathyroid secretory protein by isolated porcine parathyroid cells. Endocrinology. 1978;103:2081- 90.
54. Mayer GP, Hurst JG. Comparison of the effects of calcium and magnesium on parathyroid hormone secretion rate in calves. Endocrinology. 1978;102:1803-14.
55. DiPette DJ, Greilich PE, Nickols GA, Graham GA, Green A, Cooper CW, et al. Effect of dietary calcium supplementation on blood pressure and calciotropic hormones in mineralocorticoidsalt hypertension. J Hypertens. 1990;8:515-20.
56. Fertig A, Webley M, Lynn JA. Primary hyperparathyroidism in a patient with Conn's syndrome. Postgrad Med J. 1980;56:45-7.
57. Hellman DE, Kartchner M, Komar N, Mayes D, Pitt M. Hyperaldosteronism, hyperparathyroidism, medullary sponge kidneys, and hypertension. JAMA. 1980;244:1351-3.
58. Brunaud L, Germain A, Zarnegar R, Rancier M, Alrasheedi S, Caillard C, et al. Serum aldosterone is correlated positively to parathyroid hormone (PTH) levels in patients with primary hyperparathyroidism. Surgery. 2009;146:1035-41.
59. Chhokar VS, Sun Y, Bhattacharya SK, Ahokas RA, Myers LK, Xing Z, et al. Loss of bone minerals and strength in rats with aldosteronism. Am J Physiol Heart Circ Physiol. 2004;287: H2023-6.
60. Palmieri GM, Hawrylko J. Effects of aldosterone on the urinary excretion of total and non-dialyzable hydroxyproline. Horm Metab Res. 1977;9:507-9.
61. Sellmeyer DE, Schloetter M, Sebastian A. Potassium citrate prevents increased urine calcium excretion and bone resorption induced by a high sodium chloride diet. J Clin Endocrinol Metab. 2002;87:2008-12.
62. Goulding A, Campbell D. Dietary NaCl loads promote calciuria and bone loss in adult oophorectomized rats consuming a low calcium diet. J Nutr. 1983;113:1409-14.
63. Creedon A, Cashman KD. The effect of high salt and high protein intake on calcium metabolism, bone composition and bone resorption in the rat. Br J Nutr. 2000;84:49-56.
64. Somers MJ, Mavromatis K, Galis ZS, Harrison DG. Vascular superoxide production and vasomotor function in hypertension induced by deoxycorticosterone acetate-salt. Circulation. 2000;101:1722-8.
65. Pu Q, Neves MF, Virdis A, Touyz RM, Schiffrin EL. Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension. 2003;42:49-55.
66. Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension. 2002;40:504-10.
67. Gandhi MS, Deshmukh PA, Kamalov G, Zhao T, Zhao W, Whaley JT, et al. Causes and consequences of zinc dyshomeostasis in rats with chronic aldosteronism. J Cardiovasc Pharmacol. 2008;52:245- 52.
68. Fleckenstein A, Frey M, Fleckenstein-Grun G. Consequences of uncontrolled calcium entry and its prevention with calcium antagonists. Eur Heart J. 1983;4:43-50.
69. Ahokas RA, Sun Y, Bhattacharya SK, Gerling IC, Weber KT. Aldosteronism and a proinflammatory vascular phenotype. Role of Mg2+, Ca2+ and H2O2 in peripheral blood mononuclear cells. Circulation. 2005;111:51-7.
70. Ahokas RA, Warrington KJ, Gerling IC, Sun Y, Wodi LA, Herring PA, et al. Aldosteronism and peripheral blood mononuclear cell activation. A neuroendocrine-immune interface. Circ Res. 2003;93: e124-35.
71. Fujita T, Palmieri GM. Calcium paradox disease: calcium deficiency prompting secondary hyperparathyroidism and cellular calcium overload. J Bone Miner Metab. 2000;18:109-25.
72. Smogorzewski M, Zayed M, Zhang YB, Roe J, Massry SG. Parathyroid hormone increases cytosolic calcium concentration in adult rat cardiac myocytes. Am J Physiol. 1993;264:H1998-2006.
73. Perna AF, Smogorzewski M, Massry SG. Effects of verapamil on the abnormalities in fatty acid oxidation of myocardium. Kidney Int. 1989;36:453-7.
74. Rampe D, Lacerda AE, Dage RC, Brown AM. Parathyroid hormone: An endogenous modulator of cardiac calcium channels. Am J Physiol. 1991;261:H1945-50.
75. Deluca HF, Engstrom GW, Rasmussen H. The action of vitamin D and parathyroid hormone in vitro on calcium uptake and release by kidney mitochondria. Proc Natl Acad Sci U S A. 1962;48:1604-9.
76. Sallis JD, Deluca HF, Rasmussen H. Parathyroid hormonedependent uptake of inorganic phosphate by mitochondria. J Biol Chem. 1963;238:4098-102.
77. Sallis JD, DeLuca HF. Action of parathyroid hormone on mitochondria. Magnesium- and phosphate-independent respiration. J Biol Chem. 1966;241:1122-7.
78. Kimmich GA, Rasmussen H. The effect of parathyroid hormone on mitochondrial ion transport in the terminal portion of the cytochrome chain. Biochim Biophys Acta. 1966;113:457-66.
79. Rasmussen H, Ogata E. Parathyroid hormone and the reactions of mitochondria to cations. Biochemistry. 1966;5:733-45.
80. Touyz RM. Reactive oxygen species as mediators of calcium signaling by angiotensin II: implications in vascular physiology and pathophysiology. Antioxid Redox Signal. 2005;7:1302-14.
81. Palty R, Silverman WF, Hershfinkel M, Caporale T, Sensi SL, Parnis J, et al. NCLX is an essential component of mitochondrial Na+/Ca2+ exchange. Proc Natl Acad Sci U S A. 2010;107:436-41.
82. Kuo TH, Zhu L, Golden K, Marsh JD, Bhattacharya SK, Liu BF. Altered Ca2+ homeostasis and impaired mitochondrial function in cardiomyopathy. Mol Cell Biochem. 2002;238:119-27.
83. Rossier MF, Lesouhaitier O, Perrier E, Bockhorn L, Chiappe A, Lalevée N. Aldosterone regulation of T-Type calcium channels. J Steroid Biochem Mol Biol. 2003;85:383-8.
84. Perrier R, Richard S, Sainte-MarieY, Rossier BC, Jaisser F, Hummler E, et al. A direct relationship between plasma aldosterone and cardiac L-Type Ca2+ current in mice. J Physiol. 2005;569:153-62.
85. Schlüter KD, Weber M, Piper HM. Parathyroid hormone induces protein kinase C but not adenylate cyclase in adult cardiomyocytes and regulates cyclic AMP levels via protein kinase C-dependent phosphodiesterase activity. Biochem J. 1995;310:439-44.
86. Schlüter KD, Piper HM. Cardiovascular actions of parathyroid hormone and parathyroid hormone-related peptide. Cardiovasc Res. 1998;37:34-41.
87. Lütteke D, Ross G, Abdallah Y, Schäfer C, Piper HM, Schlüter KD. Parathyroid hormone-related peptide improves contractile responsiveness of adult rat cardiomyocytes with depressed cell function irrespectively of oxidative inhibition. Basic Res Cardiol. 2005;100:320-7.
88. Tastan I, Schreckenberg R,Mufti S, AbdallahY, Piper HM, Schlüter KD. Parathyroid hormone improves contractile performance of adult rat ventricular cardiomyocytes at low concentrations in a non-acute way. Cardiovasc Res. 2009;82:77-83.
89. Kamalov G, Ahokas RA, Zhao W, Johnson PL, Shahbaz AU, Bhattacharya SK, et al. Temporal responses to intrinsically coupled calcium and zinc dyshomeostasis in cardiac myocytes and mitochondria during aldosteronism. Am J Physiol Heart Circ Physiol. 2010;298:H385-94.
90. Goodwin KD, Ahokas RA, Bhattacharya SK, Sun Y, Gerling IC, Weber KT. Preventing oxidative stress in rats with aldosteronism by calcitriol and dietary calcium and magnesium supplements. Am J Med Sci. 2006;332:73-8.
91. Vidal A, Sun Y, Bhattacharya SK, Ahokas RA, Gerling IC,Weber KT. Calcium paradox of aldosteronism and the role of the parathyroid glands. Am J Physiol Heart Circ Physiol. 2006;290: H286-94.
92. Yang F, Nickerson PA. Effect of parathyroidectomy on arterial hypertrophy, vascular lesions, and aortic calcium content in deoxycorticosterone-induced hypertension. Res Exp Med (Berl). 1988;188:289-97.
93. Selektor Y, Ahokas RA, Bhattacharya SK, Sun Y, Gerling IC,Weber KT. Cinacalcet and the prevention of secondary hyperparathyroidism in rats with aldosteronism. Am J Med Sci. 2008;335:105-10.
94. Matzinger P. The danger model: A renewed sense of self. Science. 2002;296:301-5.
95. Weber KT. Extracellular matrix remodeling in heart failure. A role for de novo angiotensin II generation. Circulation. 1997;96:4065- 82.
96. Bell NH, Greene A, Epstein S, Oexmann MJ, Shaw S, Shary J. Evidence for alteration of the vitamin D-endocrine system in blacks. J Clin Invest. 1985;76:470-3.
97. Sawaya BP, Monier-Faugere MC, Ratanapanichkich P, Butros R, Wedlund PJ, Fanti P. Racial differences in parathyroid hormone levels in patients with secondary hyperparathyroidism. Clin Nephrol. 2002;57:51-5.
98. Zittermann A, Fischer J, Schleithoff SS, Tenderich G, Fuchs U, Koerfer R. Patients with congestive heart failure and healthy controls differ in vitamin D-associated lifestyle factors. Int J Vitam Nutr Res. 2007;77:280-8.
99. Zittermann A, Schleithoff SS, Gotting C, Dronow O, Fuchs U, Kuhn J, et al. Poor outcome in end-stage heart failure patients with low circulating calcitriol levels. Eur J Heart Fail. 2008;10:321-7.
100. Zittermann A, Schleithoff SS, Koerfer R. Vitamin D and vascular calcification. Curr Opin Lipidol. 2007;18:41-6.
101. Ogino K, Ogura K, Kinugasa Y, Furuse Y, Uchida K, Shimoyama M, et al. Parathyroid hormone-related protein is produced in the myocardium and increased in patients with congestive heart failure. J Clin Endocrinol Metab. 2002;87:4722-7.
102. Zia AA, Komolafe BO, Moten M, Ahokas RA, McGee JE, Rosenberg EW, et al. Supplemental vitamin D and calcium in the management of African-Americans with heart failure having hypovitaminosis D. Am J Med Sci. 2011;341:113-8.
103. Borkowski BJ, Cheema Y, Shahbaz AU, Bhattacharya SK,Weber KT. Cation dyshomeostasis and cardiomyocyte necrosis. The Fleckenstein hypothesis revisited. Eur Heart J. 2011;32:1846-53.
104. Cohen AJ, Roe FJ. Review of risk factors for osteoporosis with particular reference to a possible aetiological role of dietary salt. Food Chem Toxicol. 2000;38:237-53.
105. Teucher B, Dainty JR, Spinks CA, Majsak-Newman G, Berry DJ, Hoogewerff JA, et al. Sodium and bone health: impact of moderately high and low salt intakes on calcium metabolism in postmenopausal women. J Bone Miner Res. 2008;23:1477-85.
106. Lee AH, Mull RL, Keenan GF, Callegari PE, Dalinka MK, Eisen HJ, et al. Osteoporosis and bone morbidity in cardiac transplant recipients. Am J Med. 1994;96:35-41.
107. Kerschan-Schindl K, Strametz-Juranek J, Heinze G, Grampp S, Bieglmayer C, Pacher R, et al. Pathogenesis of bone loss in heart transplant candidates and recipients. J Heart Lung Transplant. 2003;22:843-50.
108. Nishio K, Mukae S, Aoki S, Itoh S, Konno N, Ozawa K, et al. Congestive heart failure is associated with the rate of bone loss. J Intern Med. 2003;253:439-46.
109. Kenny AM, Boxer R, Walsh S, Hager WD, Raisz LG. Femoral bone mineral density in patients with heart failure. Osteoporos Int. 2006;17:1420-7.
110. Frost RJ, Sonne C, Wehr U, Stempfle HU. Effects of calcium supplementation on bone loss and fractures in congestive heart failure. Eur J Endocrinol. 2007;156:309-14.
111. Abou-Raya S, Abou-Raya A. Osteoporosis and congestive heart failure (CHF) in the elderly patient: double disease burden. Arch Gerontol Geriatr. 2009;49:250-4.
112. van Diepen S, Majumdar SR, Bakal JA, McAlister FA, Ezekowitz JA. Heart failure is a risk factor for orthopedic fracture: A population-based analysis of 16,294 patients. Circulation. 2008;118:1946-52.
113. Carbone LD, Cross JD, Raza SH, Bush AJ, Sepanski RJ, Dhawan S, et al. Fracture risk in men with congestive heart failure. Risk reduction with spironolactone. J Am Coll Cardiol. 2008;52:135-8.
114. Law PH, Sun Y, Bhattacharya SK, Chhokar VS, Weber KT. Diuretics and bone loss in rats with aldosteronism. J Am Coll Cardiol. 2005;46:142-6.
115. Kamalov G, Deshmukh PA, Baburyan NY, Gandhi MS, Johnson PL, Ahokas RA, et al. Coupled calcium and zinc dyshomeostasis and oxidative stress in cardiac myocytes and mitochondria of rats with chronic aldosteronism. J Cardiovasc Pharmacol. 2009;53:414-23.
116. Schmid C, Kiowski W. Hyperparathyroidism in congestive heart failure. Am J Med. 1998;104:508-9.
117. Stefenelli T, Pacher R, Woloszczuk W, Glogar D, Kaindl F. Parathyroid hormone and calcium behavior in advanced congestive heart failure [German]. Z Kardiol. 1992;81:121-5.
118. Zittermann A, Schleithoff SS, Tenderich G, Berthold HK, Korfer R, Stehle P. Low vitamin D status: A contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol. 2003;41:105-12.
119. Sugimoto T, Tanigawa T, Onishi K, Fujimoto N, Matsuda A, Nakamori S, et al. Serum intact parathyroid hormone levels predict hospitalisation for heart failure. Heart. 2009;95:395-8.
120. Pilz S, Tomaschitz A, Drechsler C, Ritz E, Boehm BO, Grammer TB, et al. Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. Eur Heart J. 2010;31:1591-8.
121. Hagström E, Hellman P, Larsson TE, Ingelsson E, Berglund L, Sundström J, et al. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation. 2009;119:2765-71.
122. Hagström E, Ingelsson E, Sundström J, Hellman P, Larsson TE, Berglund L, et al. Plasma parathyroid hormone and risk of congestive heart failure in the community. Eur J Heart Fail. 2010;12:1186-92.
123. Anderson JL, Vanwoerkom RC, Horne BD, Bair TL, May HT, Lappé DL, et al. Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: dependent or independent risk factors? Am Heart J. 2011;162:331-9.
124. Kestenbaum B, Katz R, de Boer I, Hoofnagle A, Sarnak MJ, Shlipak MG, et al. Vitamin D, parathyroid hormone, and cardiovascular events among older adults. J Am Coll Cardiol. 2011;58:1433-41.
125. Loncar G, Bozic B, Dimkovic S, Prodanovic N, Radojicic Z, Cvorovic V, et al. Association of increased parathyroid hormone with neuroendocrine activation and endothelial dysfunction in elderly men with heart failure. J Endocrinol Invest. 2011;34: e78-85.
126. Bjorkman M, Sorva A, Tilvis R. Parathyroid hormone as amortality predictor in frail aged inpatients. Gerontology. 2009;55:601-6.
127. Schierbeck LL, Jensen TS, Bang U, Jensen G, Køber L, Jensen JE. Parathyroid hormone and vitamin D-markers for cardiovascular and all cause mortality in heart failure. Eur J Heart Fail. 2011;13:626-32.
128. Carlstedt F, Lind L, Wide L, Lindahl B, Hänni A, Rastad J, et al. Serum levels of parathyroid hormone are related to the mortality and severity of illness in patients in the emergency department. Eur J Clin Invest. 1997;27:977-81.
129. Carlstedt F, Lind L, Rastad J, Stjernstrom H, Wide L, Ljunghall S. Parathyroid hormone and ionized calcium levels are related to the severity of illness and survival in critically ill patients. Eur J Clin Invest. 1998;28:898-903.
130. Ishii J, Nomura M, Nakamura Y, Naruse H, Mori Y, Ishikawa T, et al. Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure. Am J Cardiol. 2002;89:691-5.
131. Kuwabara Y, Sato Y, Miyamoto T, Taniguchi R, Matsuoka T, Isoda K, et al. Persistently increased serum concentrations of cardiac troponin in patients with acutely decompensated heart failure are predictive of adverse outcomes. Circ J. 2007;71:1047-51.
132. Peacock 4th WF, De Marco T, Fonarow GC, Diercks D,Wynne J, Apple FS, et al. Cardiac troponin and outcome in acute heart failure. N Engl J Med. 2008;358:2117-26.
133. Zairis MN, Tsiaousis GZ, Georgilas AT, Makrygiannis SS, Adamopoulou EN, Handanis SM, et al. Multimarker strategy for the prediction of 31 days cardiac death in patients with acutely decompensated chronic heart failure. Int J Cardiol. 2009;141:284- 90.
134. Löwbeer C, Gustafsson SA, Seeberger A, Bouvier F, Hulting J. Serum cardiac troponin T in patients hospitalized with heart failure is associated with left ventricular hypertrophy and systolic dysfunction. Scand J Clin Lab Invest. 2004;64:667-76.
135. Horwich TB, Patel J, MacLellan WR, Fonarow GC. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation. 2003;108:833-8.
136. Sukova J, Ostadal P, Widimsky P. Profile of patients with acute heart failure and elevated troponin I levels. Exp Clin Cardiol. 2007;12:153-6.
137. Ilva T, Lassus J, Siirilä-Waris K, Melin J, Peuhkurinen K, Pulkki K, et al. Clinical significance of cardiac troponins I and T in acute heart failure. Eur J Heart Fail. 2008;10:772-9.
138. Sato Y, Nishi K, Taniguchi R, Miyamoto T, Fukuhara R, Yamane K, et al. In patients with heart failure and non-ischemic heart disease, cardiac troponin T is a reliable predictor of long-Term echocardiographic changes and adverse cardiac events. J Cardiol. 2009;54:221-30.
139. Miller WL, Hartman KA, Burritt MF, Grill DE, Jaffe AS. Profiles of serial changes in cardiac troponin T concentrations and outcome in ambulatory patients with chronic heart failure. J Am Coll Cardiol. 2009;54:1715-21.